For decades, scientists have called roughly 98% of the human genome “noncoding DNA.” That label was always a polite way of saying we had no idea what most of it did. The protein coding regions got the attention, the funding, the Nobel Prizes. Everything else was, at various points, dismissed as junk. That era is ending, and artificial intelligence is the reason.
AI is finally decoding the 98% of human DNA that science spent decades dismissing as junk.
A new generation of deep learning models is systematically decoding the regulatory architecture hidden across billions of base pairs, identifying functional patterns in stretches of DNA that traditional genomics essentially ignored. The implications stretch well beyond academic curiosity. Most disease associated genetic variants identified through genome wide association studies sit in these noncoding regions. Understanding what they do, and how they break, is the difference between knowing a disease has a genetic component and actually being able to do something about it.
Why Sequence Alone Was Never Enough
The core problem is deceptively simple to state and extraordinarily hard to solve. DNA does not operate like a linear instruction manual. A mutation in one location can influence gene expression thousands or even millions of base pairs away, mediated by three dimensional chromatin folding, transcription factor binding cascades, and epigenetic modifications that vary across cell types.
Traditional bioinformatics tools were built for a flatter world. They excelled at aligning sequences, identifying known motifs, and cataloging variants. They were not designed to reason about the kind of long range, context dependent, multi scale regulatory logic that actually governs how genomes function.
Convolutional neural networks changed the first part of this equation by learning motif like sequence features directly from raw DNA, bypassing the need for manual feature engineering. Models trained this way can predict chromatin accessibility, histone modifications, and transcription factor binding with impressive cell type specificity. They detect regulatory signals that conventional pattern matching misses entirely, not because the signals are invisible in the data, but because the combinatorial complexity overwhelms rule based approaches.
The real shift, though, came with scale. Early deep learning genomics models processed windows of a few hundred to a few thousand base pairs. That is enough to capture local regulatory elements but nowhere near sufficient to model the long distance interactions that define how genomes are actually organized.
Enter the Million Base Pair Models
AlphaGenome, from DeepMind, represents a significant step change. Processing sequences of approximately one million base pairs, it predicts thousands of molecular properties characterizing regulatory activity across extended genomic regions. This model exemplifies the growing trend of foundation models built for science, which enhance predictive capabilities in specialized domains.
The architecture combines convolutional layers for local pattern detection with transformer layers that allow information to flow across the entire input window. This is not just a bigger model doing the same thing. It is a qualitatively different approach that can, in principle, capture enhancer promoter interactions, insulator elements, and topological domain boundaries within a single forward pass.
The strategic significance here maps directly onto DeepMind’s broader trajectory. AlphaFold solved protein structure prediction by treating it as a pattern recognition problem at sufficient scale. AlphaGenome applies the same philosophy to genomic regulation. The pattern is unmistakable: Alphabet is systematically building AI infrastructure for biology, and each new model extends the reach of what can be predicted computationally before anyone touches a pipette.
Multimodal approaches push even further by jointly analyzing one dimensional sequence data and three dimensional chromatin structure. Research has shown that noncoding variants with similar epigenetic signatures but completely different local sequences are frequently linked by physical proximity in chromatin architecture.
Sequence only models are structurally blind to these relationships. Adding chromatin conformation data gives models access to the spatial grammar of genome regulation, the rules governing which pieces of DNA actually talk to each other inside the nucleus.
The Noncoding Variant Problem Is a Clinical Bottleneck
This matters enormously for clinical genomics. When a patient receives whole genome sequencing today, the lab can reliably interpret variants in well characterized coding regions. But the vast majority of noncoding variants get classified as “variants of uncertain significance,” a technically accurate label that is functionally useless for clinical decision making.
Frameworks like FINSURF and JARVIS are designed to break this bottleneck. FINSURF applies supervised learning to classify noncoding mutations by pathogenic impact and link them to target genes. JARVIS integrates intolerance to variation metrics, functional annotations, and raw sequence through deep learning to prioritize constrained noncoding regions, the stretches where evolution has been most aggressive about removing mutations, suggesting they serve critical functions. Studies analyzing over 3 Mb of genome sequence have helped identify the regulatory elements whose disruption these frameworks are now learning to detect.
Support vector machines and convolutional neural networks now predict how specific noncoding variants alter transcription factor binding, enabling computational characterization of variants that have zero prior experimental data. This is a practical capability that did not exist at useful accuracy five years ago.
The clinical pipeline implications are substantial. Diagnostic labs currently rely on curated databases of known pathogenic variants and established gene disease associations. AI models that can score novel noncoding variants by predicted functional impact could dramatically expand the diagnostic yield of whole genome sequencing, particularly for patients with suspected genetic conditions who receive negative results from current testing panels.
Interpretability Changes the Value Proposition
One of the more underappreciated developments in this space is the progress on interpretability. Genomics models that merely output a pathogenicity score have limited utility for biological discovery. Clinicians and researchers need to understand why a prediction was made, which nucleotide positions contributed, what motifs were implicated, and how those findings connect to known biology.
Novel architectures using variable size filters and dense connections are specifically designed to detect sequence patterns across multiple scales while remaining amenable to interpretation. Methods that extract the key nucleotide patterns driving predictions are effectively reverse engineering regulatory grammar from trained models, exposing rules embedded in DNA that decades of experimental molecular biology had not yet surfaced.
This transforms the value proposition from prediction to discovery. A model that can tell you a variant is probably damaging is useful. A model that can tell you it is probably damaging because it disrupts a specific binding motif within a constrained regulatory element that interacts with a distant promoter through chromatin looping is a genuine research tool.
Who Benefits, Who Should Pay Attention
The immediate beneficiaries are pharmaceutical companies and biotech firms working on genetically informed drug discovery. The ability to computationally prioritize noncoding variants and link them to target genes accelerates the identification of novel therapeutic targets, particularly in complex diseases like autoimmune disorders, neuropsychiatric conditions, and cardiovascular disease where the genetic architecture is overwhelmingly noncoding.
Diagnostic companies and clinical genomics laboratories stand to gain as well, though regulatory validation will be a gating factor. The FDA and equivalent agencies in Europe and Asia have been cautious about AI driven clinical genomic interpretation, and rightly so. The consequences of false positives and false negatives in this domain are not abstract. They affect treatment decisions, reproductive planning, and family counseling.
Academic researchers benefit from what amounts to a massive expansion of functional annotation across the genome. Regions that were previously opaque to analysis become interpretable, opening new lines of investigation in developmental biology, evolutionary genomics, and disease mechanism research.
The organizations best positioned to capitalize are those with both computational infrastructure and access to large, well phenotyped genomic datasets. This gives substantial advantages to large technology companies with biology divisions, major medical centers with biobanks, and national genomics programs like the UK Biobank and All of Us in the United States.
What People Are Overlooking
Two things tend to get lost in the excitement. First, training data bias remains a serious concern. Most large scale genomic datasets are heavily skewed toward populations of European descent. Models trained primarily on these datasets may perform less accurately when applied to underrepresented populations, potentially widening health disparities rather than narrowing them.
This is not a hypothetical risk. It is an observed problem in existing polygenic risk score models, and there is no reason to assume deep learning approaches are immune.
Second, the gap between computational prediction and experimental validation is wide and expensive to cross. A model can predict that a noncoding variant disrupts a regulatory element with high confidence, but proving that prediction requires functional experiments, often in relevant cell types that are difficult to culture.
The field needs to invest in high throughput experimental validation pipelines that can keep pace with computational prediction. Without that feedback loop, model improvement will eventually plateau.
The Direction This Points
The convergence of long context genomic models, multimodal sequence and structure integration, and improved interpretability methods points toward a future where computational analysis becomes the primary screening layer for genomic interpretation.
Experimental work will not disappear, but its role will shift increasingly toward validation and mechanistic follow up rather than initial discovery.
Within three to five years, it is reasonable to expect that AI driven noncoding variant interpretation will become a standard component of clinical whole genome sequencing pipelines, at least for research use and likely for some clinical applications pending regulatory approval.
The models will improve as training datasets grow more diverse and as experimental validation data feeds back into model refinement.
The broader lesson extends beyond genomics. What is happening with DNA analysis mirrors a pattern visible across scientific AI: models trained at sufficient scale on the right data discover structure that human experts could not see, not because the experts were incompetent, but because the complexity exceeded what any human or traditional algorithm could process.
The genome is one of the most information dense objects in biology. It was always going to require computational tools that could match that density. Those tools are arriving now, and the consequences for medicine, drug development, and our basic understanding of human biology will unfold for decades.
